{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:21:55Z","timestamp":1791336115090,"version":"4.3.1"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 HL51045"],"award-info":[{"award-number":["R37 HL51045"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL 59469, R01 HL79424"],"award-info":[{"award-number":["R01 HL 59469, R01 HL79424"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL93685"],"award-info":[{"award-number":["R01 HL93685"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL118808"],"award-info":[{"award-number":["R01 HL118808"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Mid-Atlantic Affiliate Beginning","award":["765273U"],"award-info":[{"award-number":["765273U"]}]},{"name":"American Heart Association National Scientist Development","award":["10SDG3770011"],"award-info":[{"award-number":["10SDG3770011"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.pharmthera.2014.10.003","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T21:44:17Z","timestamp":1414791857000},"page":"12-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"special_numbering":"C","title":["PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer"],"prefix":"10.1016","volume":"147","author":[{"given":"Anindita","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Durrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi N.","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh C.","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2014.10.003_bb0005","doi-asserted-by":"crossref","first-page":"19079","DOI":"10.1073\/pnas.1013077107","article-title":"Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy","volume":"107","author":"Adamo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0010","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0015","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/CIRCULATIONAHA.112.000056","article-title":"Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial","volume":"127","author":"Andersen","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1464-5491.2003.01084.x","article-title":"Association between fasting glucose and C-reactive protein in middle-aged subjects","volume":"21","author":"Aronson","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.ijir.3901513","article-title":"Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study","volume":"19","author":"Aversa","year":"2007","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-5491.2007.02298.x","article-title":"Chronic administration of Sildenafil improves markers of endothelial function in men with type 2 diabetes","volume":"25","author":"Aversa","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0035","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2008.06.122","article-title":"PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model","volume":"1230","author":"Black","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0050","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/mol.113.090043","article-title":"Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal\/genitourinary cancer cells","volume":"85","author":"Booth","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1158\/1535-7163.MCT-14-0172","article-title":"Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs","volume":"13","author":"Booth","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0060","article-title":"PDE5 inhibitors enhance Celecoxib killing in multiple tumor types","author":"Booth","year":"2014","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1203\/01.PDR.0000147736.27672.15","article-title":"Sildenafil citrate (Viagra) induces cardioprotective effects after ischemia\/reperfusion injury in infant rabbits","volume":"57","author":"Bremer","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0070","doi-asserted-by":"crossref","first-page":"H2272","DOI":"10.1152\/ajpheart.00654.2010","article-title":"Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA\/Rho-kinase pathway","volume":"300","author":"Chau","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0075","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1073\/pnas.1006965107","article-title":"Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction","volume":"107","author":"Das","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0080","doi-asserted-by":"crossref","first-page":"H1236","DOI":"10.1152\/ajpheart.00100.2009","article-title":"ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia\u2013reperfusion injury in mice","volume":"296","author":"Das","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0085","doi-asserted-by":"crossref","first-page":"38644","DOI":"10.1074\/jbc.M606142200","article-title":"Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia\/reoxygenation in adult cardiomyocyte","volume":"281","author":"Das","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0090","doi-asserted-by":"crossref","first-page":"12944","DOI":"10.1074\/jbc.M404706200","article-title":"Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling","volume":"280","author":"Das","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0095","doi-asserted-by":"crossref","first-page":"29572","DOI":"10.1074\/jbc.M801547200","article-title":"Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta","volume":"283","author":"Das","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0100","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gr.GR-1649R","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"11","author":"Dean","year":"2001","journal-title":"Genome Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","article-title":"Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes","volume":"25","author":"Desouza","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0110","doi-asserted-by":"crossref","first-page":"e19329","DOI":"10.1371\/journal.pone.0019329","article-title":"The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1\/P-glycoprotein transporter","volume":"6","author":"Ding","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0115","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1253\/circj.CJ-09-0338","article-title":"Why do we still not have cardioprotective drugs?","volume":"73","author":"Downey","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0120","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1073\/pnas.0705891104","article-title":"Hydrogen sulfide attenuates myocardial ischemia\u2013reperfusion injury by preservation of mitochondrial function","volume":"104","author":"Elrod","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0125","first-page":"303","article-title":"Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts","volume":"16","author":"Epstein","year":"1984","journal-title":"Adv Cyclic Nucleotide Protein Phosphorylation Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.urology.2006.05.011","article-title":"Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat","volume":"68","author":"Ferrini","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb4000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000068446","article-title":"The heart in human dystrophinopathies","volume":"99","author":"Finsterer","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0135","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Fisher","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0140","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0145","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/1097-0142(19851215)56:12<2762::AID-CNCR2820561207>3.0.CO;2-E","article-title":"Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring","volume":"56","author":"Friess","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12916-014-0185-3","article-title":"Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials","volume":"12","author":"Giannetta","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0155","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","article-title":"Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging","volume":"125","author":"Giannetta","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0160","first-page":"237","article-title":"Chemotherapy-induced resistance by ATP-binding cassette transporter genes","volume":"1775","author":"Gillet","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0165","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-5347(05)65856-9","article-title":"Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy","volume":"166","author":"Goluboff","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0090-4295(98)00513-5","article-title":"Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing","volume":"53","author":"Goluboff","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.diabres.2007.02.006","article-title":"Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes","volume":"78","author":"Grover-Paez","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study","volume":"4","author":"Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-012-0848-7","article-title":"Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer","volume":"31","author":"Hamilton","year":"2013","journal-title":"World J Urol"},{"issue":"Pt 10","key":"10.1016\/j.pharmthera.2014.10.003_bb0190","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1242\/jcs.113.10.1671","article-title":"Rising behind NO: cGMP-dependent protein kinases","volume":"113","author":"Hofmann","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/stem.789","article-title":"Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice","volume":"30","author":"Hoke","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0200","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.yjmcc.2011.02.013","article-title":"cGMP\/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion","volume":"50","author":"Inserte","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0898-6568(96)00112-X","article-title":"Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021","volume":"8","author":"Ito","year":"1996","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1359-4117.2003.01076.x","article-title":"Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells","volume":"3","author":"Joe","year":"2003","journal-title":"J Exp Ther Oncol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0215","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1006\/jmcc.1999.0983","article-title":"Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxide-dependent mechanism","volume":"31","author":"Jones","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0220","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.arcmed.2012.08.006","article-title":"Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors","volume":"43","author":"Karami-Tehrani","year":"2012","journal-title":"Arch Med Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0225","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/CIRCULATIONAHA.111.065300","article-title":"Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity","volume":"125","author":"Kim","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0230","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1517\/14656566.2011.600306","article-title":"Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors","volume":"12","author":"Kloner","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0235","doi-asserted-by":"crossref","first-page":"H1558","DOI":"10.1152\/ajpheart.00865.2013","article-title":"Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO\/SIRT1\/PGC-1alpha signaling","volume":"306","author":"Koka","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2013.01.031","article-title":"Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia\/reperfusion injury in type 2 diabetic mice","volume":"60","author":"Koka","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0245","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Koka","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00395-012-0249-5","article-title":"Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in type 2 diabetic hearts","volume":"107","author":"Koka","year":"2012","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0255","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/sj.ijir.3901612","article-title":"Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats","volume":"20","author":"Kovanecz","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb5000","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.2174\/138161281939131127110156","article-title":"Sildenafil and cardioprotection","volume":"19","author":"Kukreja","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2003.11.001","article-title":"Cardioprotection with phosphodiesterase-5 inhibition \u2014 a novel preconditioning strategy","volume":"36","author":"Kukreja","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0270","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jacc.2011.09.086","article-title":"Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection","volume":"59","author":"Kukreja","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0275","first-page":"e30","article-title":"Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases","volume":"16","author":"Kukreja","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0265","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.vph.2005.02.010","article-title":"Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications","volume":"42","author":"Kukreja","year":"2005","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0280","first-page":"787","article-title":"67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis","volume":"123","author":"Kumazoe","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0285","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0295","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Li","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0290","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1535-7163.MCT-13-0048","article-title":"Sulindac selectively inhibits colon tumor cell growth by activating the cGMP\/PKG pathway to suppress Wnt\/beta-catenin signaling","volume":"12","author":"Li","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0300","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0006-2952(99)00200-2","article-title":"Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines","volume":"58","author":"Lim","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0305","first-page":"4972","article-title":"Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells","volume":"9","author":"Lim","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0315","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bcp.2012.07.023","article-title":"Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways","volume":"84","author":"Liu","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0898-6568(01)00216-9","article-title":"Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase","volume":"14","author":"Liu","year":"2002","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0320","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-1119(98)00303-5","article-title":"Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3\u2032,5\u2032-cyclic nucleotide phosphodiesterase","volume":"216","author":"Loughney","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0325","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0031-6997(24)01457-1","article-title":"Guanylyl cyclases and signaling by cyclic GMP","volume":"52","author":"Lucas","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0330","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tips.2014.05.003","article-title":"Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond","volume":"35","author":"Lukowski","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0335","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1073\/pnas.1001360107","article-title":"Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes","volume":"107","author":"Lukowski","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0340","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0345","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.ijir.3901454","article-title":"The effect of vardenafil on endothelial function of brachial and cavernous arteries","volume":"18","author":"Mazo","year":"2006","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0350","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1475-2840-11-67","article-title":"Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning","volume":"11","author":"Miki","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0355","doi-asserted-by":"crossref","first-page":"19611","DOI":"10.1073\/pnas.0911046106","article-title":"Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms","volume":"106","author":"Moench","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0360","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/03602532.2011.556122","article-title":"The glutathione transferase kappa family","volume":"43","author":"Morel","year":"2011","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0365","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1172\/JCI656","article-title":"Leukocyte\u2013endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion","volume":"101","author":"Morigi","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1006\/jmcc.2001.1491","article-title":"Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium","volume":"34","author":"Muller-Ehmsen","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0375","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1464-410X.2005.05413.x","article-title":"Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and\/or vardenafil monotherapy after radical retropubic prostatectomy","volume":"95","author":"Mydlo","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Nagendran","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0385","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1158\/1078-0432.CCR-07-0744","article-title":"Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence","volume":"13","author":"Narayanan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0390","doi-asserted-by":"crossref","first-page":"C661","DOI":"10.1152\/ajpcell.00459.2005","article-title":"Physiological role of ROCKs in the cardiovascular system","volume":"290","author":"Noma","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0400","doi-asserted-by":"crossref","first-page":"H1263","DOI":"10.1152\/ajpheart.00324.2002","article-title":"Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits","volume":"283","author":"Ockaili","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0395","first-page":"1267","article-title":"The pharmacology of cancer resistance","volume":"27","author":"O'Connor","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0405","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/01.ju.0000164286.47518.1e","article-title":"The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations","volume":"174","author":"Ohebshalom","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0410","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0735-1097(03)00081-0","article-title":"Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation","volume":"41","author":"Pagani","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0415","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-410X.2010.09343.x","article-title":"Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function","volume":"106","author":"Pahlajani","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000080104","article-title":"Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy","volume":"72","author":"Patil","year":"2004","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0425","first-page":"3961","article-title":"Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis","volume":"61","author":"Piazza","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0430","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCULATIONAHA.108.822072","article-title":"Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice","volume":"119","author":"Pokreisz","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0435","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/sj.ijir.3900713","article-title":"The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial","volume":"13","author":"Porst","year":"2001","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0440","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1089\/ars.2010.3343","article-title":"Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes","volume":"14","author":"Przyklenk","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0445","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.ijir.3901588","article-title":"Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review","volume":"20","author":"Rambhatla","year":"2008","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0450","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/eurheartj\/ehm010","article-title":"Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18","volume":"28","author":"Ray","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0455","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0460","first-page":"29","article-title":"Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses","volume":"8","author":"Resnick","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0465","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4161\/cbt.28553","article-title":"PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells","volume":"15","author":"Roberts","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0470","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2004.10.002","article-title":"Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk","volume":"47","author":"Rosano","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0475","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrd893","article-title":"Phosphodiesterase 5 inhibitors: current status and potential applications","volume":"1","author":"Rotella","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0490","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.91438.2007","article-title":"Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice","volume":"294","author":"Salloum","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0495","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1161\/CIRCULATIONAHA.108.843979","article-title":"Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia\/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide","volume":"120","author":"Salloum","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0500","doi-asserted-by":"crossref","first-page":"H1347","DOI":"10.1152\/ajpheart.00544.2011","article-title":"Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia\/reperfusion injury: role of hydrogen sulfide","volume":"302","author":"Salloum","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0505","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.yjmcc.2007.08.014","article-title":"Adenosine A1 receptor mediates delayed cardioprotective effect of sildenafil in mouse","volume":"43","author":"Salloum","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0510","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.yjmcc.2006.10.015","article-title":"Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits","volume":"42","author":"Salloum","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0485","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.RES.0000066853.09821.98","article-title":"Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart","volume":"92","author":"Salloum","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0515","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2002-01-0075","article-title":"Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells","volume":"101","author":"Sarfati","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0520","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1172\/JCI70731","article-title":"PDE5 inhibitor efficacy is estrogen dependent in female heart disease","volume":"124","author":"Sasaki","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0525","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1464-410X.2006.06441.x","article-title":"Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function","volume":"98","author":"Schiff","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0530","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1006\/jmcc.1996.0358","article-title":"The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart","volume":"29","author":"Schultz","year":"1997","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0535","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1096\/fj.00-0538com","article-title":"Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure","volume":"15","author":"Senzaki","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0540","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1158\/0008-5472.CAN-10-3820","article-title":"Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0545","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0550","first-page":"60","article-title":"Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues","volume":"36","author":"Singer","year":"1976","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0555","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/dmrr.921","article-title":"Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients","volume":"25","author":"Stirban","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0560","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0565","doi-asserted-by":"crossref","first-page":"329","DOI":"10.18388\/abp.1993_4806","article-title":"ATP-sensitive K+ channel in mitochondria","volume":"40","author":"Szewczyk","year":"1993","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0570","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0575","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1006\/jmcc.2001.1500","article-title":"Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart","volume":"34","author":"Tejero-Taldo","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0580","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.juro.2007.08.007","article-title":"Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer","volume":"178","author":"Teloken","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0585","first-page":"3338","article-title":"Exisulind induction of apoptosis involves guanosine 3\u2032,5\u2032-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin","volume":"60","author":"Thompson","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0590","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/beta-catenin-mediated transcription in human breast tumor cells","volume":"4","author":"Tinsley","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0595","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1158\/1535-7163.MCT-09-0758","article-title":"Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G","volume":"8","author":"Tinsley","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0600","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1475-2840-11-89","article-title":"Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia\u2013reperfusion injury","volume":"11","author":"Van der Mieren","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0605","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/jpet.109.154468","article-title":"cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium","volume":"330","author":"Vandeput","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0610","doi-asserted-by":"crossref","first-page":"e45243","DOI":"10.1371\/journal.pone.0045243","article-title":"Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice","volume":"7","author":"Varma","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0615","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1161\/01.CIR.0000074043.46437.44","article-title":"Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones","volume":"107","author":"Varo","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0620","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0625","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yjmcc.2007.10.006","article-title":"Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection","volume":"44","author":"Wang","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0630","first-page":"479","article-title":"Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival","volume":"2","author":"Whitehead","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0635","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1161\/01.CIR.99.16.2157","article-title":"Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice","volume":"99","author":"Xi","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0640","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(00)00275-4","article-title":"Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction","volume":"155","author":"Xi","year":"2000","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0645","first-page":"H2418","article-title":"Glycolipid RC-552 induces delayed preconditioning-like effect via iNOS-dependent pathway in mice","volume":"277","author":"Xi","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0650","doi-asserted-by":"crossref","first-page":"H5","DOI":"10.1152\/ajpheart.00920.2001","article-title":"Evidence that NOS2 acts as a trigger and mediator of late preconditioning induced by acute systemic hypoxia","volume":"283","author":"Xi","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0655","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tips.2011.02.019","article-title":"Phosphodiesterases and cardiac cGMP: evolving roles and controversies","volume":"32","author":"Zhang","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0660","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.cellsig.2008.08.012","article-title":"Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes","volume":"20","author":"Zhang","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0675","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/jmcc.2001.1510","article-title":"Late preconditioning elicited by activation of adenosine A3 receptor in heart: role of NF-kappa B, iNOS and mitochondrial KATP channel","volume":"34","author":"Zhao","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0665","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1006\/jmcc.1997.0390","article-title":"Role of inducible nitric oxide synthase in pharmacological \u201cpreconditioning\u201d with monophosphoryl lipid A","volume":"29","author":"Zhao","year":"1997","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0670","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/01.CIR.102.8.902","article-title":"Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors: evidence from gene-knockout mice","volume":"102","author":"Zhao","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0680","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jcb.20286","article-title":"Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells","volume":"94","author":"Zhu","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmthera.2014.10.003_bb0685","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1582-4934.2011.01376.x","article-title":"Type 2 diabetic obese db\/db mice are refractory to myocardial ischaemic post-conditioning in vivo: potential role for Hsp20, F1-ATPase delta and Echs1","volume":"16","author":"Zhu","year":"2012","journal-title":"J Cell Mol Med"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814001892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814001892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T01:26:29Z","timestamp":1746494789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725814001892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":138,"alternative-id":["S0163725814001892"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}